litlas
Log inCreate account

David R. Lynch

Active 1984–2025

121
Papers
22,553
Citations
73
h-index
116
i10-index

Citations

Citations per year for David R. Lynch1985: 1 citations1986: 2 citations1987: 2 citations1988: 4 citations1989: 5 citations1990: 3 citations1991: 6 citations1992: 3 citations1993: 5 citations1994: 3 citations1995: 8 citations1996: 20 citations1997: 25 citations1998: 29 citations1999: 28 citations2000: 29 citations2001: 38 citations2002: 35 citations2003: 36 citations2004: 42 citations2005: 71 citations2006: 84 citations2007: 122 citations2008: 141 citations2009: 134 citations2010: 206 citations2011: 239 citations2012: 226 citations2013: 200 citations2014: 249 citations2015: 207 citations2016: 184 citations2017: 210 citations2018: 155 citations2019: 652 citations2020: 612 citations2021: 586 citations2022: 481 citations2023: 358 citations2024: 646 citations2025: 305 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,727 citing papers, 28% of this breakdownChina: 471 citing papers, 7.7% of this breakdownUnited Kingdom: 461 citing papers, 7.5% of this breakdownGermany: 459 citing papers, 7.5% of this breakdownItaly: 365 citing papers, 5.9% of this breakdownSpain: 301 citing papers, 4.9% of this breakdownFrance: 286 citing papers, 4.6% of this breakdownCanada: 241 citing papers, 3.9% of this breakdownAustralia: 217 citing papers, 3.5% of this breakdownJapan: 151 citing papers, 2.5% of this breakdownNetherlands: 133 citing papers, 2.2% of this breakdownSwitzerland: 119 citing papers, 1.9% of this breakdown
0%28%Other 19.9%

Institutions

Fields

  • Medicine52.1%
  • Neuroscience25.7%
  • Biochemistry, Genetics and Molecular Biology19%
  • Immunology and Microbiology1.5%
  • Psychology0.4%
  • Nursing0.3%
  • Other1%

Topics

  • Autoimmune Neurological Disorders and Treatments9.2%
  • Genetic Neurodegenerative Diseases5.3%
  • Neuroscience and Neuropharmacology Research5.2%
  • Mitochondrial Function and Pathology4.4%
  • Parkinson's Disease Mechanisms and Treatments3.8%
  • Peripheral Neuropathies and Disorders3.2%
  • Other68.9%

Coauthors

All papers

Open in search
  1. Paraneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma

    Authors: Josep Dalmau, Erdem Tüzün, Haiyan Wu, Jaime Masjuan, Jeffrey Rossi, Alfredo Voloschin, Joachim M. Baehring, Haruo Shimazaki, Reiji Koide, Dale King, Warren Mason, Lauren Sansing, Marc A. Dichter, Myrna R. Rosenfeld, David R. Lynch - Annals of Neurology 2007 cited by 2,466

  2. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies

    Authors: Josep Dalmau, Amy J. Gleichman, Ethan G. Hughes, Jeffrey Rossi, Xiaoyu Peng, Meizan Lai, Scott Dessain, Myrna R. Rosenfeld, Rita J. Balice‐Gordon, David R. Lynch - The Lancet Neurology 2008 cited by 3,459

  3. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)

    Authors: David R. Lynch, Melanie Chin, Martin B. Delatycki, S. H. Subramony, Manuela Corti, J. Chad Hoyle, Sylvia Boesch, Wolfgang Nachbauer, Caterina Mariotti, Katherine D. Mathews, Paola Giunti, George Wilmot, Theresa A. Zesiewicz, Susan Perlman, Angie Goldsberry, Megan A. O’Grady, Colin J. Meyer - Annals of Neurology 2020 cited by 296

  4. Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis

    Authors: Ethan G. Hughes, Xiaoyu Peng, Amy J. Gleichman, Meizan Lai, Lei Zhou, Ryan Tsou, Thomas D. Parsons, David R. Lynch, Josep Dalmau, Rita J. Balice‐Gordon - Journal of Neuroscience 2010 cited by 1,127

  5. Mitochondrial dysfunction in the development and progression of neurodegenerative diseases

    Authors: Joseph Johnson, Elizabeth Mercado‐Ayón, Yesica Mercado-Ayon, Yi Dong, Sarah Halawani, Lucie Ngaba, David R. Lynch - Archives of Biochemistry and Biophysics 2020 cited by 252

  6. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study

    Authors: Núria Gresa‐Arribas, Maarten J. Titulaer, Abiguei Torrents, Esther Aguilar, Lindsey McCracken, Frank Leypoldt, Amy J. Gleichman, Rita J. Balice‐Gordon, Myrna R. Rosenfeld, David R. Lynch, Francesc Graus, Josep Dalmau - The Lancet Neurology 2013 cited by 1,286

  7. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension

    Authors: David R. Lynch, Melanie Chin, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, Angie Goldsberry, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Megan O’Grady, Susan Perlman, S. H. Subramony, George Wilmot, Theresa A. Zesiewicz, Colin J. Meyer - Movement Disorders 2022 cited by 115

  8. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia

    Authors: David R. Lynch, Jennifer Farmer, Lauren Hauser, Ian A. Blair, Qing Qing Wang, Clementina Mesaros, Nathaniel W. Snyder, Sylvia Boesch, Melanie Chin, Martin B. Delatycki, Paola Giunti, Angela Goldsberry, Chad Hoyle, Michael G. McBride, Wolfgang Nachbauer, Megan O’Grady, Susan Perlman, S. H. Subramony, George Wilmot, Theresa A. Zesiewicz, Colin J. Meyer - Annals of Clinical and Translational Neurology 2018 cited by 166

  9. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location

    Authors: Meizan Lai, Ethan G. Hughes, Xiaoyu Peng, Lei Zhou, Amy J. Gleichman, Huidy Shu, Sabrina Matà, Daniel Kremens, Roberta Vitaliani, Michael D. Geschwind, Luís Bataller, Robert G. Kalb, Rebecca Davis, Francesc Graus, David R. Lynch, Rita J. Balice‐Gordon, Josep Dalmau - Annals of Neurology 2009 cited by 803

  10. Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale

    Authors: S. H. Subramony, William May, David R. Lynch, C. M. Gomez, Kenneth H. Fischbeck, Maurice B. Hallett, J. Paul Taylor, Roneé E. Wilson, Tetsuo Ashizawa - Neurology 2005 cited by 388

  11. Mortality in Friedreich Ataxia

    Authors: Amy Y. Tsou, Erin K. Paulsen, Sarah J. Lagedrost, Susan Perlman, Katherine D. Mathews, George Wilmot, Bernard Ravina, Arnulf H. Koeppen, David R. Lynch - Journal of the Neurological Sciences 2011 cited by 307

  12. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data

    Authors: David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S. H. Subramony, George Wilmot, Theresa A. Zesiewicz, Lisa A. Weissfeld, Colin J. Meyer - Annals of Clinical and Translational Neurology 2023 cited by 47

  13. Friedreich Ataxia: Clinical Features and New Developments

    Authors: Medina Keita, Kellie McIntyre, Layne N. Rodden, Kim Schadt, David R. Lynch - Neurodegenerative Disease Management 2022 cited by 73

  14. Anti–N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in children and adolescents

    Authors: Nicole R. Florance, Rebecca Davis, Christopher Wai Kei Lam, Christina L. Szperka, Lei Zhou, Saba Ahmad, Cynthia Campen, Heather E. Moss, Nadja G. Peter, Amy J. Gleichman, Carol Glaser, David R. Lynch, Myrna R. Rosenfeld, Josep Dalmau - Annals of Neurology 2009 cited by 1,097

  15. Functional Consequences of α-Synuclein Tyrosine Nitration

    Authors: Roberto Hodara, Erin H. Norris, Benoit I. Giasson, Amanda J. Mishizen-Eberz, David R. Lynch, Virginia M.‐Y. Lee, Harry Ischiropoulos - Journal of Biological Chemistry 2004 cited by 283

  16. Natural History of Friedreich Ataxia

    Authors: Christian Rummey, Louise A. Corben, Martin B. Delatycki, George Wilmot, S. H. Subramony, Manuela Corti, Khalaf Bushara, Antoine Duquette, Christopher M. Gómez, J. Chad Hoyle, Richard Roxburgh, Lauren Seeberger, Grace Yoon, Katherine D. Mathews, Theresa A. Zesiewicz, Susan Perlman, David R. Lynch - Neurology 2022 cited by 63

  17. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia

    Authors: Victoria Profeta, Kellie McIntyre, McKenzie Wells, Courtney Park, David R. Lynch - Expert Opinion on Investigational Drugs 2023 cited by 38

  18. Anti-NMDA Receptor Encephalitis Antibody Binding Is Dependent on Amino Acid Identity of a Small Region within the GluN1 Amino Terminal Domain

    Authors: Amy J. Gleichman, Lynn A. Spruce, Josep Dalmau, Steven H. Seeholzer, David R. Lynch - Journal of Neuroscience 2012 cited by 285

  19. Double-blind, Randomized and Controlled Trial of EPI-743 in Friedreich’s Ataxia

    Authors: Theresa A. Zesiewicz, Jason L. Salemi, Susan Perlman, Kelly L. Sullivan, Jessica Shaw, Yangxin Huang, Charles J. Isaacs, Clifton L. Gooch, David R. Lynch, Matthew B. Klein - Neurodegenerative Disease Management 2018 cited by 84

  20. Distinct cleavage patterns of normal and pathologic forms of α‐synuclein by calpain I in vitro

    Authors: Amanda J. Mishizen-Eberz, Rodney P. Guttmann, Benoit I. Giasson, George A. Day, Roberto Hodara, Harry Ischiropoulos, Virginia M.‐Y. Lee, John Q. Trojanowski, David R. Lynch - Journal of Neurochemistry 2003 cited by 160

  21. Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia

    Authors: Charles A. Galea, Aamira Huq, Paul J. Lockhart, Geneieve Tai, Louise A. Corben, Eppie M. Yiu, Lyle C. Gurrin, David R. Lynch, Sarah Gelbard, Alexandra Dürr, Françoise Pousset, Michael Parkinson, Robyn Labrum, Paola Giunti, Susan Perlman, Martin B. Delatycki, Marguerite V. Evans‐Galea - Annals of Neurology 2015 cited by 152

  22. Predictors of loss of ambulation in Friedreich's ataxia

    Authors: Christian Rummey, Jennifer Farmer, David R. Lynch - EClinicalMedicine 2020 cited by 66

  23. Central Nervous System Therapeutic Targets in Friedreich Ataxia

    Authors: Ian H. Harding, David R. Lynch, Arnulf H. Koeppen, Massimo Pandolfo - Human Gene Therapy 2020 cited by 49

  24. Measuring Friedreich ataxia

    Authors: David R. Lynch, Jennifer Farmer, Amy Y. Tsou, Susan Perlman, S. H. Subramony, C. M. Gomez, Tetsuo Ashizawa, George Wilmot, Robert B. Wilson, Laura J. Balcer - Neurology 2006 cited by 218